A Randomized Controlled Trial of combination of Cognitive-Behavioral Therapy (CBT) with Selective Serotonin Reuptake Inhibitors (SSRIs) Therapy for Obsessive-Compulsive Disorder (OCD) and Generalized Anxiety Disorder (GAD)

A Randomized Controlled Trial to evaluate the efficacy and security of combination of Cognitive-Behavioral Therapy (CBT) with Selective Serotonin Reuptake Inhibitors (SSRIs) Therapy for Obsessive-Compulsive Disorder (OCD) and Generalized Anxiety Disorder (GAD)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10001123

Enrollment

Unknown

Registered

2010-12-10

Start date

2009-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder(OCD) and Generalized Anxiety Disorder(GAD)

Interventions

GAD-A:combination of 16 times of CBT and therapeutic dose of SSRIs

OCD-B:therapeutic dose of SSRIs

GAD-B:therapeutic dose of SSRIs

OCD-A:combination of 12 times of CBT and therapeutic dose of SSRIs

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18 to 65 years old inpatients or outpatients who can read and can understand Chinese, no restrictions on gender; 2. In accordance with the diagnostic criteria of OCD or GAD in DSM-IV and ICD-10; 3. Before enrollment, OCD patients' Y-BOCS>=16, GAD patients' HAMA>=14.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women, or women that prepare to get pregnant during the study; 2. With mental disorders that are not listed inclusion criteria; 3. Reseacher considers that the patient has physical disease or inadequate treatment (such as diabetes, angina and high blood pressure, active hepatitis); 4. History of seizures or narrow-angle glaucoma; 5. Attend other clinical trials and would not or cannot complete the course of the treatment; 6. The OCD patients that have no significant effects after taking the maximum dose of paroxetine, sertraline or fluvoxamine; 7. The GAD patients that reveal no significant effects after taking the maximum dose of paroxetine or sertraline; 8. Reseacher considers that the patient has the risk of suicide or harm to others.

Design outcomes

Primary

Measure	Time frame
Yale-Brown Obsessive–Compulsive Scale(OCD group);Hamilton Anxiety Scale(GAD group;	—

Secondary

Measure	Time frame
Hamilton Anxiety Scale(OCD group);Clinical Global Impression Scale(both of OCD and GAD);Global Assessment Function(both of OCD and GAD group);Sheehan Disability Assessment Scale(both of OCD and GAD group);	—

Countries

China

Contacts

Public ContactYueqin Huang

dengy@mail.tsinghua.edu.cn+86 10 82802836

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026